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Calibrating the dose per monitor unit (DMU) for individual patients is important 
to deliver the prescribed dose in radiation therapy. We have developed a DMU 
calculation method combining measurement data and calculation with a simplified 
Monte Carlo method for the double scattering system in proton beam therapy at 
the National Cancer Center Hospital East in Japan. The DMU calculation method 
determines the clinical DMU by the multiplication of three factors: a beam spreading 
device factor FBSD, a patient-specific device factor FPSD, and a field-size correction 
factor FFS(A). We compared the calculated and the measured DMU for 75 dose fields 
in clinical cases. The calculated DMUs were in agreement with measurements in 
± 1.5% for all of 25 fields in prostate cancer cases, and in ± 3% for 94% of 50 
fields in head and neck (H&N) and lung cancer cases, including irregular shape 
fields and small fields. Although the FBSD in the DMU calculations is dominant as 
expected, we found that the patient-specific device factor and field-size correction 
also contribute significantly to the calculated DMU. This DMU calculation method 
will be able to substitute the conventional DMU measurement for the majority of 
clinical cases with a reasonable calculation time required for clinical use.
PACS number: 87.55.kh
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I. INTRODUCTION
Calibrating the dose per monitor unit (DMU) for individual patients is important to deliver 
the prescribed dose in radiation therapy. The DMU is defined as a ratio of irradiated dose at 
the isocenter to an amount of charge in an ionization reference chamber expressed in monitor 
units. This DMU for proton beam therapy depends on patient-specific beam conditions, such 
as beam energy, the width of spread-out Bragg peak (SOBP), the thickness of range shifter 
(RS), the shapes of a range compensator, and an aperture collimator. For patient-specific beam 
conditions, most proton therapy facilities have been obtaining the DMU not by calculation in 
the treatment planning system, but by measurement in a water-equivalent phantom represent-
ing the treatment condition. This is because it is difficult to accurately simulate the behavior 
of protons passing through complex combination of beam delivery devices and entering into 
the patient with possible lateral heterogeneity.(1) Additionally, it takes much time and labor at 
present to measure the DMU for patient-specific proton fields in clinical routine.
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For DMU calculations, Kooy et al.(2,3) developed a semi-empirical calculation method for 
a range modulated proton beam. It is based on the fact that the DMU depends on the ratio of 
the entrance dose and the reference dose. They obtained a result that the DMU depends on 
a single factor (R - M) / M, where R is the distal range and M is modulation width. On the 
other hand, Sahoo et al.(4) calculated the DMU based on measurements of dose at isocenter in 
various conditions of beam delivery devices. They expressed the DMU as a product of eight 
factors that are based on measurements for sampled conditions. The calculation accuracy of 
their method was within 2% for 99% of 623 distinct fields. Their methods calculate the DMU 
in homogeneous water-equivalent phantoms, not in heterogeneous media such as a patient.
Currently, approaches with Monte Carlo simulations have been studied to improve accuracy 
of proton dose prediction in tissue heterogeneity.(5,6,7,8,9,10) From these studies, it was found 
that the DMU calculation method should consider the effect of heterogeneous media such as a 
patient and a range compensator in proton therapy in the same way heterogeneous correction is 
required for DMU calculation in photon therapy.(11) Thus, we expect that the DMU calculation 
with the Monte Carlo method has a potential of solving these problems. However, since it takes 
much time to calculate the DMU with the full Monte Carlo method, reduction of calculation 
time is required to apply the Monte Carlo method for calculating the DMU in a patient routinely. 
Meanwhile, we have already developed a simplified Monte Carlo (SMC) method, with which 
we can quickly calculate dose distributions accurately.(12,13)
In this paper, looking ahead to calculate the DMU in heterogeneous media as a final goal, 
we have developed, at present, a new DMU calculation method in a uniform phantom with 
the SMC method for the double scattering system of National Cancer Center Hospital East 
(NCCHE). We show results of comparison between the calculated and the measured DMUs in 
a water-equivalent phantom for 75 clinical cases. 
 
II. MATERIALS AND METHODS
A.  Beam line
We measured and calculated proton dose distributions formed by the double scattering system 
of NCCHE.(14) We used a proton beam with one of the energies 235, 190 or 150 MeV provided 
by a 235 MeV proton cyclotron and an energy selection system comprised of carbon degraders 
and a beam collimator. A treatment gantry with the double-scattering system has beam-shaping 
devices, as shown in Fig. 1. Thickness of the binary first scatterer and a type of second scatterer 
Fig. 1. Scheme of beam line arrangement.
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are determined by the proton energy. The maximum field size formed by the double-scattering 
system is 200 × 200 mm2. A ridge filter is used to form a spread-out Bragg peak (SOBP). The 
SOBP widths can be selected from 30 mm to 100 mm at intervals of 10 mm. A transmission 
dose monitor is placed downstream of the ridge filter and binary range shifter. A patient aperture 
collimator is placed downstream of a range compensator to sharpen the lateral dose falloff in 
the peripheral region of PTV.
B.  Detectors
While a PTW 30013 was used for absolute dose measurement, a PTW 2D Array seven29  (PTW 
Freiburg GmbH, Freiburg, Germany) was used for relative dose measurements. The PTW 
30013 is a Farmer type chamber with a sensitive volume of ϕ 6.1 mm × 23.4 mm (0.6 cc). It 
was used to measure the dose in a uniform water-equivalent phantom under the uniform field 
conditions where patient-specific devices (a range compensator and an aperture) were removed. 
For the patient-specific QA, we measure the dose at the isocenter in a uniform water-equivalent 
phantom under the nonuniform field condition with a patient aperture collimator and a range 
compensator. While the PTW 30013 was used for the field size larger than 4 × 4 cm2, the PTW 
31015 was used for the field size smaller than 4 × 4 cm2. In this paper, data for fields more than 
4 × 4 cm2 were selected. The PTW 2D Array seven29 has 729 ionization chambers in a 10 mm 
pitch 27 × 27 array. Spezi et al.(15) reported the successful application of this detector to radiation 
therapy and verified the performance. The sensitive volume of a unit chamber is 5 mm × 5 mm × 
5 mm and the ionization chambers of the array are open to the air. The offset thickness from 
the entrance surface to the center of the sensitive volume was 8 mm in water-equivalent length 
(WEL). The chamber array was used to measure the relative dose under both the uniform field 
condition and a possible nonuniform field condition that patient-specific devices were inserted. 
To compare the calculations and measurements under the same conditions, we integrated the 
calculated dose distribution in a rectangular area with a detector cell size of 6.1 mm × 23.4 mm 
for the PTW 30013 or 5 mm × 5 mm for the PTW 2D Array seven29.
C.  Calculation of DMU
In NCCHE, the DMU measurement in a patient-specific condition is made with a patient-specific 
aperture collimator and a range compensator, as shown in Fig. 1(b). To derive the DMU in the 
patient-specific conditions by calculation, we defined the DMU in the patient-specific condi-
tions (DMUcalc,clinical) as a product of the standard DMU (DMUmeas,STD) and a clinical beam 
delivering condition factor (Fcalc,clinical). The DMUmeas,STD is a DMU measured in our standard 
beam measurement (STD) conditions, as shown in Fig. 1(d). Details of the STD conditions 
are described in the Table 1. The Fcalc,clinical can be written by multiplication of three factors: 
a beam-spreading device factor (FBSD), a patient-specific device factor (FPSD), and a field-size 
correction factor (FFS(A)) in the following way.
Table 1. Beam delivery and measurement conditions for STD, BSD, PSD, FS(A).
  STD BSD PSD FS(A)
 Energy 190 MeV Patient-specific Patient-specific Patient-specific
 RS Thickness 0 mm Patient-specific Patient-specific 0 mm
 SOBP Width 80 mm Patient-specific Patient-specific 80 mm
 Collimator to Axis Distance 300 mm 300 mm Patient-specific 300 mm
 Range Compensator Nonexistent Nonexistent Patient-specific Nonexistent
 Patient Collimator 185×185 mm2 185×185 mm2 Patient-specific A×A mm2
 Target Phantom Phantom Phantom Phantom
 Measurement Point Center of SOBP Center of SOBP Patient- specific Center of SOBP
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 DMUcalc,clinical ≡ DMUmeas,STD × Fcalc,clinical (1)
 Fcalc,clinical ≡ FBSD × FPSD × FFS(A) (2)
 FBSD ≡ DMUmeas,BSD / DMUmeas,STD (3)
 FPSD ≡ DMUcalc,PSD / DMUcalc,BSD (4)
 FFS(A) ≡ fmeas,FS(A) / fcalc,FS(A) (5)
 fcalc,FS(A) ≡ DMUcalc,FS(A) / DMUcalc,FS(A=185) (6)
 fmeas,FS(A) ≡ DMUmeas,FS(A) / DMUmeas,FS(A=185) (7)
The subscripts STD, BSD, PSD, and FS in equations denote beam delivery and measurement 
conditions, respectively, as summarized in Table 1; the prefixes, meas and calc, of the subscripts 
in the equations denote that the value was obtained by either measurement or calculation.
The FBSD represents the effect of commonly used devices, such as the first and second scat-
terers, a range shifter, and a SOBP filter, on the DMU. It is defined as a ratio of measured DMUs 
in the BSD condition, as shown in Fig. 1(c) to that in the STD condition. In the BSD condition, 
while the beam spreading devices are set in the same way as in the patient-specific condition, 
a patient-specific aperture collimator is replaced by a standard collimator (a collimator with a 
square aperture of 185 × 185 mm2), and a range compensator is removed. The FBSD is obtained 
by measurements since the combination of parameters of commonly used devices are limited.
The FPSD represents the effects of custom-made devices for an individual patient (a patient-
specific aperture collimator and a range compensator) and an air-gap between the collimator 
and the patient surface on the DMU. It is defined as a ratio of calculated DMUs by using the 
SMC in the BSD condition to that in the PSD condition, as shown in Fig. 1(b). In the PSD 
condition, all devices are set at a patient-specific condition.
The FFS(A) corrects the discrepancy of FPSD for the smaller field size. The effect is called a 
field-size effect, as mentioned in the Materials & Methods section C.3 below. This factor is 
defined as a ratio of the measured field-size factor fmeas,FS(A) to the calculated field-size factor 
fcalc,FS(A) expressed as a function of the mean of distances between edge points of an aperture 
collimator and the isocenter. The fmeas,FS(A) (or fcalc,FS(A)) is defined as a ratio of measured (or 
calculated) DMUs in the FS condition with square-shaped aperture of “A” mm a side to that 
with square-shaped aperture of 185 mm a side.
C.1 Measurement of beam spreading device factor: FBSD 
The beam spreading device factor FBSD is a ratio of the DMUmeas,BSD to DMUmeas,STD. We mea-
sured the DMUmeas,BSD in a polyethylene phantom at the position corresponding to the center 
of SOBP identical to the isocenter using the PTW 30013. The thickness of the phantom on the 
PTW 30013 was calculated by an equation: proton range -SOBP/2 - RS)/WELR, where the 
SOBP and RS are the water-equivalent width of spread-out Bragg peak and the water-equivalent 
thickness of the range shifter, respectively. The WELR is the water-equivalent thickness ratio 
of the polyethylene phantom.
We measured the DMUmeas,BSD for eight ridge filters with the SOBP width from 30 mm 
WEL to 100 mm WEL at intervals of 10 mm WEL for three energies. For each proton energy, 
the RS thickness was varied from 0 mm WEL to the maximum value up to 120 mm WEL at 
intervals of 10 mm or 20 mm WEL, depending on the width of the SOBP. Figure 2 shows the 
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measurement results of the FBSD. All datasets were normalized by the dose at the isocenter in 
the STD condition. The FBSD decreased with an increase in the RS thickness and an increase in 
the SOBP width due to the following three reasons. Firstly, since the lower energy protons passing 
through the thicker RS deposit larger energy in the ionization reference chamber, the number of 
protons reaching the center of SOBP decreases for the same MU, resulting in decrease in FBSD. 
Secondly, a ridge filter with a larger SOBP width increases the average energy of protons reach-
ing the isocenter, resulting in a decreased dose at the isocenter for the same MU. In addition, 
since average energy of protons entering into the ionization reference chamber decreases with 
an increase in the SOBP width, the number of protons reaching the center of SOBP decreases 
for the same MU. Thirdly, as the RS thickness and the SOBP width increases, more material 
is inserted in the beam course. Then proton scattering and nuclear interaction increase in the 
inserted material, resulting in decrease of proton fluence at the isocenter.
C.2  Calculation of patient-specific device factor: FPSD
For DMUcalc,PSD and DMUcalc,BSD calculations, we used the simplified Monte Carlo method 
(SMC).(12,13) It tracks individual protons in a range compensator, an aperture collimator, and 
a phantom by calculating the range loss and scattering in materials using the water-equivalent 
model(16) and the Highlands’s equation.(17) Scattering effect in commonly used devices is 
integrated and expressed by using the single Gaussian effective-source model with the model 
parameters determined by measurements.(18,19) The measured depth-dose distribution in water 
was used to obtain the relative dose deposit in a patient voxel. The voxel dimension in the 
phantom was taken as 2 mm × 2 mm × 2 mm and the number of particles is determined so 
that the statistical error was less than 1%. To shorten the calculation time, we have adopted 
general-purpose computing on graphics processing units (GPGPU) technique in this DMU 
calculation.(20) Since the calculation time is about 1 min for each proton field, this method is 
practical in clinical use.
Fig. 2. Change of FBSD for three energies. 
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C.3  Measurement of field-size factor: FFS(A) 
The field-size factor FFS(A) is the ratio of fmeas,FS(A) to fcalc,FS(A). We measured the DMUmeas,FS(A) 
at the isocenter in the FS setting for each of three energies, using a collimator with a square-
shaped aperture. We prepared five collimators with an aperture side of 40, 50, 70, 100, 185 mm 
and measured the DMUmeas, FS(A) for each of them. We also calculated the dose distributions 
under the same conditions. We used the SMC as stated above for calculations. The calculation 
voxel dimension in the phantom was taken as 2 mm × 2 mm × 2 mm. The number of particles 
is determined so that the statistical error is less than 1%.
Figure 3 shows the FFS(A), fmeas,FS(A), fcalc,FS(A). Datasets for each of three energies were 
normalized to unity for the case where a collimator with an aperture side of 185 mm was used. 
The circles show the measurement results. The blue solid line shows the calculation results 
using the SMC. The red thick line shows the FFS(A) is the ratio of fmeas,FS(A) to fcalc,FS(A). The 
fmeas,FS(A) is the measured DMU in the FS(A) condition normalized by the measured DMU 
in the FS(185) condition. The fcalc,FS(A) is the calculated one corresponding to the fmeas,FS(A). 
The measurement results showed that the DMUmeas,FS(A) decreased with a decrease in the 
aperture size of the collimator for proton energies of 190 and 235 MeV. The DMUmeas,FS(A) 
decreases by about 5% when the aperture size of collimator varies from 185 mm to 40 mm 
for 235 MeV protons. While the measured aperture effect was less than 1% for protons with 
energies, 190 MeV and 150 MeV, it was significant for 235 MeV protons. On the other hand, 
the calculated DMUcalc,FS(A) was almost 1.0 for the collimator aperture size larger than 40 mm 
and began to decrease for the collimator aperture size less than 30 mm.
In general, the dose at the isocenter consists of on-axis contribution from protons entering 
in the phantom along the beam central axis, and off-axis contribution from protons entering in 
the phantom at neighboring positions of the beam central axis and reaching the isocenter due 
to the initial angular spread and scattering in the phantom. In larger field sizes, the protons that 
enter in the phantom at the beam central axis and escape from the axis at the isocenter balance 
the off-axis contribution. In such cases, no field-size effect is observed. As the field size shrinks, 
the balance is broken due to decreased off-axis contribution and the field-size effect begins to 
appear. On the other hand, edge-scattered protons in the collimator begin to contribute to the 
dose at the isocenter as the distance between the beam central axis and the collimator aperture 
edge gets smaller. Thus the field-size effect is a net result of such complex phenomena. It is 
apparent that the observed discrepancy between the measured and calculated field-size effect 
implies that the current SMC calculation model is not enough to reproduce the field-size effect. 
Although we consider at present that the possible causes of the discrepancy may be the current 
Gaussian model of initial angular distribution of protons and/or the model of the edge scattering 
in the collimator, it is an open problem for future study. At present, we correct the difference by 
the field-size factor, FFS(A). For an irregular-shaped aperture found in the clinical case, a mean 
Fig. 3. Comparison of calculation and measurement results for field-size effect. The circles show the measurement results, 
the blue solid line shows the calculation results, and the red thick line shows the F(FS(A)) that is the ratio of measurement 
and calculation. 
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aperture radius is calculated and the field-size factor FFS(A) for a collimator with the same mean 
aperture radius is used for the correction. We defined the mean aperture radius as a mean of 
distances between all the collimator edge points and the isocenter. The collimator edge points 
were given in the same resolution of the planning CT image.
D.  DMU measurement in clinical conditions
We compared the calculated and measured dose distribution on the isocenter plane for seven 
clinical fields of H&N, prostate, and lung cancer cases. We mounted a stack of polyethylene 
phantoms on the PTW 2D array seven29 detector to measure a dose distribution at the same 
water-equivalent depth as the water-equivalent depth of the isocenter for clinical field. The 
beam line device parameters and the phantom thickness are shown in Table 2, corresponding 
to the seven clinical cases.
We also compared the measured and calculated results for 75 clinical fields of H&N, lung, 
and prostate cancer cases (25 fields for each), including the aforementioned seven fields. We 
redefined Fmeas,clinical and Fcalc,clinical by the following equations: 
 Fmeas,clinical ≡ DMUmeas,clinical / DMUmeas,STD (8)
 Fcalc,clinical ≡ FBSD × FPSD × FFS(A) (9)
Here, DMUmeas,clinical is a DMU measured in a patient-specific beam condition with a patient-
aperture collimator and a range compensator. The dose was measured in a polyethylene phantom 
at the water-equivalent depth of isocenter by using the PTW 30013.
 
III. RESULTS & DISCUSSION 
Figure 4 shows the measured and calculated relative dose distributions for the seven clinical 
fields. All datasets were normalized by the DMUmeas,STD. Measured dose distributions were in 
good agreement with calculated ones. Some of them, such as the X profile of H&N 3 and the 
Y profile of lung 1, had nonuniform dose distributions around the isocenter. In these cases, the 
measured DMU may have included a dose error originating from misalignment of the dose 
monitor relative to the range compensator in the nonuniform dose region. In order to reduce 
such an error, the dose monitor should be placed in a more uniform dose region.
Figure 5 shows the relation between the Fmeas,clinical and other calculated or measured factors 
(Fcalc,clinical, FBSD, FPSD, FFS(A)) of 25 proton dose fields for each of three clinical sites. Upper 
graphs show the values of Fcalc,clinical, FBSD, FPSD, and FFS(A) versus Fmeas,clinical. The error bars 
for the FPSD and Fcalc,clinical were calculated from peak-to-peak dose variation within a cubic 
region of 2 mm on a side around the isocenter obtained by the calculated dose distribution. 
Table 2. Beam delivery and measurement conditions for individual clinical fields. 
  Energy SOBP Width RS Thickness PE Thickness
  (MeV) (mm) (mm-WEL) (mm)
 Prostate 1 235 60 55.1 162
 Prostate 2 235 60 48.7 169
 Lung 1 190 50 62.6 66
 Lung 2 150 50 21.5 52
 H&N 1 150 70 22.0  22
 H&N 2 150 70 26.1 31
 H&N 3 150 60 8.7 20
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Fig. 4. Measured and calculated relative dose distributions for 7 clinical beams. Left figures show the shape of aperture 
collimators. Center and right figures show x and y dose profiles, respectively. Red circles are measured doses and blue 
lines are calculated dose distributions.
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Since the statistical errors were estimated to be smaller than 0.1% for the detection volume of 
the Farmer chamber, we ignored them. We notice from the graphs in the Fig. 5 that the FBSD is 
a dominant factor of the Fcalc,clinical, since the FPSD and FFS(A) were almost 1.0. Here, we focus 
on the Fcalc,clinical and FBSD to evaluate contribution of each factor in the calculation. Lower 
graphs of Fig. 5 show the differences of the Fcalc,clinical and FBSD from the Fmeas,clinical. The 
mean, standard deviation (SD), maximum, and minimum of the difference are summarized in 
Table 3 for the FPSD and FFS(A). These results show that agreement between the Fcalc,clinical and 
Fmeas,clinical is better than that between the FBSD and Fmeas,clinical. Thus the FPSD and FFS(A) serve 
to improve calculation accuracy of the DMU significantly.
For prostate cancer cases, field sizes clustered around 5 cm. The Fcalc,clinical agrees with 
Fmeas,clinical within ± 1.5% of the Fmeas,clinical for all fields. Values of the Fmeas,clinical cluster around 
1.1 since the anatomic location and shape of the target are very similar patient by patient. The 
mean value of FBSD minus Fmeas,clinical is systematically larger than that of the Fcalc,clinical minus 
Fmeas,clinical, and the both SDs are very small. Therefore, in prostate cancer cases, we could 
obtain the Fcalc,clinical only by adding the difference of the mean values as a correction factor 
to the FBSD. We also notice in the rightmost upper graph of Fig. 5 that the difference comes 
mainly from the significant deviation of the FFS(A) from unity. It corresponds to the fact that the 
FFS(A) deviates from unity mostly in the highest energy, 235 MeV, used for prostate cancers. 
Fig. 5. (upper) The relation between measured (Fmeas,clinical) and calculated factors (Fcalc,clinical, FBSD, FPSD, FFS) of 75 
proton dose fields. (lower) The difference of Fcalc,clinical or FBSD from Fmeas,clinical. The error bars for FPSD and Fcalc,clinical 
were calculated from peak-to-peak dose variation within a cubic region of 2 mm on a side around the measurement point.
Table 3. Mean, SD, maximum (each of over- and underestimation) of difference of calculation from measurement 
for 75 clinical dose fields.
  No. of Fields  Mean SD Max. Min.
 H&N 25
 Fcalc,clinical - Fmeas,clinical 0.78% 1.73% 4.93% -2.70%
   FBSD - Fmeas,clinical 0.92% 2.58% 7.09% -2.91%
 Lung 25 Fcalc,clinical - Fmeas,clinical -0.19% 1.58% 2.79% -3.76%   FBSD - Fmeas,clinical 0.47% 2.37% 5.56% -2.93%
 Prostate 25 Fcalc,clinical - Fmeas,clinical 0.53% 0.42% 1.26% -0.21%
   FBSD - Fmeas,clinical 2.21% 0.55% 3.08% 0.54%
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For the lung and H&N cancer cases, the field sizes distribute between 3 cm to 12 cm in 
mean radius, as shown in Fig. 6. The Fcalc,clinical agrees with Fmeas,clinical within ± 2.5% of the 
Fmeas,clinical for 94% of 50 fields. The variation of the difference, Fcalc,clinical minus Fmeas,clinical, is 
larger than that of prostate cancer cases, as shown in Table 3. For H&N and lung cancer cases, 
the SDs were 1.7% and 1.6%, and maximum differences in plus and minus sides were +4.9%, 
-2.7% and +2.8%, -3.8%, respectively.
We examined the relation between effect of the possible setup error on the error of the dif-
ference and the aperture size of the collimator. Figure 6 shows dependence of the difference 
and its error on the mean aperture radius of collimator for each of the three proton energies. 
Errors larger than 2.5% are observed for the collimators with a mean aperture radius less than 
70 mm. In these cases, measurement uncertainties caused by the setup error in the region with 
a nonuniform dose distribution are as large as those shown by the error bars. We also consider 
here the possible inaccuracy of the present model of the field-size correction. In the present 
model, we assume that the FFS(A) is a function of two parameters: the initial proton energy 
and field size. However, it may also be affected by other conditions: the RS thickness, SOBP 
width, and the depth of isocenter. Since the error of difference is large for the collimator with 
small aperture size, as shown in Fig. 6, and the field-size effect is significant for collimator with 
smaller aperture size, as shown in Fig. 3, more study for the small proton field will be required 
to improve calculation accuracy of the DMU.
 
IV. CONCLUSIONS
We have developed a DMU calculation method combining measurement data and calcula-
tion with a simplified Monte Carlo method for the double scattering system of NCCHE. The 
DMUclinical is represented by the DMUmeas,STD multiplied by Fclinical. The Fclinical is defined by 
multiplication of three factors: the beam spreading device factor FBSD, the patient-specific 
device factor FPSD, and the field-size factor FFS(A). The FBSD is obtained by measurements for 
limited combinations of three beam delivery conditions: the proton energy, the SOBP width, 
and the RS thickness. The FPSD is obtained by calculations using the SMC method. The FFS(A) 
is obtained empirically, based on the measurements. Although the FBSD is a dominant factor in 
the DMU calculation method, the FPSD and the FFS(A) also contribute significantly to the DMU 
calculation. The calculated DMUs agreed with measurements within ± 1.5% for all of 25 fields 
for prostate cancer cases and within ± 3% for 94% of 50 fields for H&N and lung cancer cases. 
Since the calculation time is within 1 min for each field, this method will be applicable to routine 
clinical use. Therefore, this method can be applied safely to determination of the DMU for all 
prostate cancer cases. In addition, it can be applied to determination of the DMU for most of 
the H&N and lung cancer cases.
 
Fig. 6. The dependence of difference between Fmeas,clinical and Fcalc,clinical on field size. The error bars were calculated from 
peak-to-peak dose variation within a cubic region of 2 mm on a side around the measurement point.
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